Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Filing (0000899243-20-019846)

Filing Details

Accession Number:
0000899243-20-019846
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-07-21 19:19:24
Reporting Period:
2020-07-20
Accepted Time:
2020-07-21 19:19:24
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1812364 Relay Therapeutics Inc. RLAY Biological Products, (No Disgnostic Substances) (2836) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1816130 Mark Murcko C/O Relay Therapeutics, Inc.
399 Binney Street, 2Nd Floor
Cambridge MA 02139		 Yes No No No
Reported Non-Derivative Transactions
Show Other Fields >>
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-07-20 281,617 $0.00 718,123 No 4 C Direct
Common Stock Acquisiton 2020-07-20 278,829 $0.00 996,952 No 4 C Direct
Common Stock Acquisiton 2020-07-20 25,000 $20.00 1,021,952 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Show Other Fields >>
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Convertible Preferred Stock Disposition 2020-07-20 1,000,000 $0.00 281,617 $0.00
Common Stock Series B Convertible Preferred Stock Disposition 2020-07-20 990,099 $0.00 278,829 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Direct
Footnotes
  1. Each share of Series A Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date.
  2. Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date.
  3. On July 20, 2020, the reporting person purchased 25,000 shares of Common Stock of the Issuer at a price of $20.00 per share pursuant to an underwritten public offering.